Strategic funding Monteris Medical has secured substantial growth capital, including a $28M Series E and a $35M growth investment backed by Trinity Capital in 2026, signaling strong investor confidence and potential for expanded commercialization efforts in neurosurgical robotics and LITT technologies.

Expansion opportunities Recent product and capability expansions, such as the NeuroBlate NB3 FullFire 1.6mm laser probe and integration with Symphony Robotics, indicate opportunities to cross-sell enhanced robotic-assisted LITT solutions to existing neuro-oncology and epilepsy treatment centers.

Clinical evidence NeuroBlate’s demonstrated clinical benefits—short hospital stays, minimal complications, and low readmission rates—can be leveraged to engage hospitals and surgeons focused on value-based care and reduced inpatient costs in brain tumor and epilepsy programs.

Strategic collaborations Partnerships with robotics and imaging ecosystems (for example Symphony Robotics) present a channel for co-marketing and bundled offerings to large health systems seeking integrated neurosurgical robotics and LITT platforms.

Targeted markets With a mid-market size and a specialty focus in brain surgery, Monteris should target high-volume neuroscience centers, academic medical centers, and cancer institutes that are actively expanding minimally invasive neurosurgical options and MR-guided ablation therapies.